This includes the webinar series (presentations, handouts, and the audience QAs recorded from the live broadcast) and SAM credit. 


Speakers:

Lauren Ritterhouse 
MD, PhD

Jonathan Nowak
MD, PhD

Ahmet Zehir
PhD

Series Description: Examining the mutational profile of tumors has become much easier because of the advances and accessibility of next-generation sequencing techniques. Analyzing the genetic signatures of tumors might identify patients who have higher chances of responding to checkpoint inhibition. Various studies have shown how the mutational burden correlates with greater efficacy of anti-PD-L1/PD-1 therapies, however tumor mutational burden (TMB) testing methodology and classification have not yet been standardized in clinical practice. This educational webinar series will provide information regarding current best practices in TMB testing, interpretation, and reporting.

Webinars include: (Click "Topic" tab for descriptions)

  • Tumor Mutational Burden: Clinical and Diagnostic Utilization in Oncology 
    Speaker: Lauren Ritterhouse
    Recorded: June 27, 2018
  • Tumor Mutational Burden: Best Practices to Address Clinical and Technical Challenges 
    Speaker: Jonathan Nowak
    Recorded: August 28, 2018
  • Tumor Mutational Burden: Result Reporting and Application to Improve Patient Care
    Speaker: Ahmet Zehir
    Recorded: September 26, 2018

 

Duration: 3 hr

Level of Instruction: Basic

Last day to purchase course and claim credit: June 27, 2019

Maximum SAM credit available: 3.0

  • To access the entire series +SAM, click the "Add to Basket" button located on the right.
  • To access individual webinars +SAM, click on the "Purchase Individual Topics" button on the right, and select the particular webinar(s) that you would like to access.

 

This is a three-part series exploring how measuring tumor mutational burden can improve patient care. If you'd like more information about the series go here.

This program has been supported through an educational grant from Bristol-Myers Squibb.


How to claim credit: To earn SAM credit, all learners must watch the webinar, achieve a minimum score of 80% on the online quiz, and complete an online survey. To access the quiz, click "Submit credit" on the course homepage or click on "My Credit" on the menu to the left and then "submit credit" for the appropriate course.

This course is approved by the American Board of Pathology for a maximum of 3.0 SAM credits. Physicians should only claim credit commensurate with the extent of their participation in the activity. Participants must successfully complete the online modular exams (answering at least 80% of the questions in a topic module correctly).

SAM questions edited by: Alan Brown, MD & Honey Reddi, PhD


You may also be interested in:

Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

Course Information
Course Date:
September 26, 2018
Course Objectives
  • Describe laboratory and bioinformatic factors that can influence TMB calculation.
  • Describe challenges and opportunities in the implementation of TMB testing in the clinical laboratory.
  • Describe the clinical utilization of tumor mutational burden (TMB) in oncology.
  • Discuss the various ways by which TMB can be reported back to the clinicians and patients.
  • Define TMB and the rationale for its use as a biomarker for immunotherapy in oncology.
  • Describe the underlying mutational processes that give rise to a tumor's mutational burden
Tumor Mutational Burden: Clinical and Diagnostic Utilization in Oncology (+SAM)

Speaker:

Lauren Ritterhouse, MD, PhD

Moderator:

Susan Hsiao, MD

 

Description:  This webinar will cover the background and rationale for the use of tumor mutational burden (TMB) as a biomarker for immunotherapy in oncology. The various biomarkers that have been evaluated for immunotherapy will be explored and a discussion of TMB’s role and use in oncology will be made. The course will cover an overview of immunotherapy drugs, targets, and tumor types for which TMB has been used as a biomarker.

Duration: 1 hr

Last day to purchase course and claim credit: June 27, 2019

SAM credit available for this webinar: 1.0

Learning Objectives:

  • Describe the clinical utilization of TMB in oncology.
  • Define TMB and the rationale for its use as a biomarker for immunotherapy in oncology.
ProductAddPrice
Ritterhouse (+SAM)
AMP Member Price:$0.00
Non-Member Price:$0.00
Tumor Mutational Burden: Best Practices to Address Clinical and Technical Challenges (+SAM)

Speaker:

Jonathan Nowak, MD, PhD 

Moderator:

Jeremy Segal, MD, PhD

 

Description: This webinar will cover the methodology for calculating tumor mutational burden (TMB) and will review technical considerations that can impact TMB calculation. The utility of detecting the underlying mutational processes that determine a tumor's mutational burden will also be discussed. The course will cover an overview of immunotherapy drugs, targets, and tumor types for which TMB has been used as a biomarker.

Duration: 1 hr

Last day to purchase course and claim credit: June 27, 2019

SAM credit available for this webinar: 1.0

Learning Objectives:

  • Describe laboratory and bioinformatic factors that can influence TMB calculation.
  • Describe the underlying mutational processes that give rise to a tumor's mutational burden
ProductAddPrice
Nowak (+SAM)
AMP Member Price:$0.00
Non-Member Price:$0.00
Tumor Mutational Burden: Result Reporting and Application to Improve Patient Care (+SAM)

Speaker:

      Ahmet Zehir, PhD     

Moderator:

Jonathan Nowak, MD, PhD

Description: As tumor mutational burden (TMB) is gaining traction as a predictive biomarker for immunotherapy, the challenge of reporting TMB back to the treating oncologists and patients in an informative way still exists. In this webinar, we will discuss strategies of implementing TMB in the clinical laboratory, how different TMB values reported from various assays compare to each other, and how to communicate the results in a clear way.

Duration: 1 hr

Last day to purchase course and claim credit: June 27, 2019

SAM credit available for this webinar: 1.0

Learning Objectives:

  • Describe challenges and opportunities in the implementation of TMB testing in the clinical laboratory.
  • Discuss the various ways by which TMB can be reported back to the clinicians and patients.
ProductAddPrice
Zehir (+SAM)
AMP Member Price:$0.00
Non-Member Price:$0.00
Individual topic purchase: Selected
American Board of Pathology
Self-Assessment Module: 3.00
Products
TMB Series 1 (+SAM)
AMP Regular Member: $0.00
AMP Technologist Member: $0.00
AMP Associate Member: $0.00
Non-member Price: $0.00